RCEL — Avita Medical Inc.

Summary of AVITA Medical, Inc. Q4 and Full Year 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Revenue: $17.6 million, down from $18.4 million in Q4 2024.
• Full Year Revenue: Approximately $71.6 million, representing an 11% increase over 2024.
• Gross Margin: Q4 gross margin was 81.2%, down from 87.6% in the prior year; full year gross margin was 82.1%, down from 85.8%.
• Operating Expenses: Q4 operating expenses totaled $24.7 million, a 5% decrease year-over-year, with a notable reduction in sales and marketing expenses.
• Cash Position: Ended Q4 with $18.2 million in cash and marketable securities, with a significant reduction in net cash used, declining to $5.1 million in Q4 from $10.1 million in Q2.

2. Strategic Updates and Business Highlights

• Focused on disciplined execution, refining commercial strategies, and enhancing growth positioning for 2026.
• Resolved reimbursement uncertainties for RECELL, with 6 of 7 Medicare administrative contractors (MACs) publishing payment rates, which is expected to normalize utilization.
• Emphasis on increasing adoption and repeat use of products (RECELL, Cohealyx, and PermeaDerm) within existing accounts, primarily burn and trauma centers.
• Clinical studies for Cohealyx and PermeaDerm are progressing, with data expected in 2026 to support their market adoption.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between $80 million and $85 million, reflecting growth of 12% to 19% over 2025.
• Anticipated growth driven by normalization of RECELL utilization and expanded use of Cohealyx and PermeaDerm within existing accounts.
• The company aims for consistent quarter-by-quarter execution rather than relying on one-time events for growth.

4. Bad News, Challenges, or Points of Concern

• Q4 revenue decline compared to the previous year raises concerns about immediate growth momentum.
• Gross margin pressures due to product mix and inventory reserves, although still above 80%.
• Dependency on the resolution of the seventh MAC's reimbursement rate, with ongoing engagement but no timeline provided for resolution.
• Potential risks associated with the adoption rates of Cohealyx and PermeaDerm, which are still in early stages of market penetration.

5. Notable Q&A Insights

• Management clarified that the $15.4 million revenue covenant is not indicative of guidance but rather provides flexibility and reduces covenant risk.
• There is confidence in gradual growth from Q4 into Q1 2026, with expectations for continued improvement in utilization.
• Discussions highlighted the importance of clinical champions in driving the adoption of new products and the ongoing administrative processes involved in MAC reviews.
• Management expressed optimism about the integration of Cohealyx and PermeaDerm into existing accounts, which could further drive RECELL utilization.

Overall, AVITA Medical is positioning itself for a more stable and predictable growth trajectory in 2026, focusing on execution and operational discipline while navigating challenges related to reimbursement and product adoption.